AbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s ...

The Gubra drug a peptide engineered to be an analog for amylin, a hormone that helps regulate blood sugar and food intake. It is specifically designed to bind to and activate amylin and calcitonin ...

But human amylin can form amyloid fibers, which can destroy insulin-producing cells in the pancreas. At the core of our research we want to understand the complex effects of insulin on amylin's ...

Thus far, the drug combo has shown impressive weight loss in animal and human trials, and Amylin is expecting to announce favorable results from phase 2 trials following positive top-line data.

In addition, there will be a $350 million up-front payment as Abbvie takes over the reins of GUB-014295 (referred to as Gubamy), a long-acting analog of the satiety hormone amylin, currently in phase ...

Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for ...

Zealand Pharma’s search for a partner for its amylin-based obesity therapy petrelintide remains ongoing, with no agreement announced in its 2024 earnings report. The company has yet to secure a ...

Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...

ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025Oral small ...

It has been announced that following Bristol-Myers Squibb’s (BMS) successful acquisition of Amylin Pharmaceuticals, AstraZeneca (AZ) has made an initial payment of approximately US $3.2 billion ...

Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...

GUB014295 is a long-acting amylin analog currently being evaluated ... AbbVie announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) issued a positive opinion ...